Parkinson’s UK is pleased to announce the release of the next tranche of the £1million funding to Keapstone Therapeutics.
 

Keapstone Therapeutics was launched in March 2017 by Parkinson’s UK and the University of Sheffield.  It is part of Parkinson’s UK’s new Virtual Biotech venture and combines world-leading research from the University with funding and expertise fr...

Parkinson’s UK has held its first ever Drug Discovery Workshop in an effort to unlock new treatments by seeking new ways to progress academic research. 

The event, which was attended by researchers from across the world, aimed to help delegates understand how commercialising their scientific discoveries can open up research to wider funding streams and allow them to...

Keapstone Therapeutics, the single-asset virtual biotech created by University of Sheffield with funding from Parkinson’s UK, held a board meeting on 15 May 2017 in Sheffield. 

The board took decisions on the strategy for funding of future stages of the research programme, and provided guidance to the Joint Steering Committee on medium-term research directions.  The b...

The University of Sheffield and Parkinson’s UK have launched a new £1million virtual biotech company in the next stage[1] of a pioneering research programme to create new drugs for Parkinson’s.

In a partnership that is the first of its kind, Keapstone Therapeutics will combine world-leading research from the University with funding and expertise from the charity to he...

Parkinson's UK and MedGenesis Therapeutix Inc. announced today that the Phase 2 clinical trial evaluating the safety and efficacy of glial cell line-derived neurotrophic factor (GDNF) in Parkinson's disease, delivered via intermittent bilateral intraputamenal infusions using convection enhanced delivery (CED) and conducted at Southmead Hospital by the North Bristol N...